Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use
Authors
Keywords
-
Journal
CNS DRUGS
Volume 35, Issue 6, Pages 691-700
Publisher
Springer Science and Business Media LLC
Online
2021-05-31
DOI
10.1007/s40263-021-00830-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
- (2020) Robert T. Naismith et al. CNS DRUGS
- Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis
- (2019) Sudhir Kumar Yadav et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study
- (2019) Michael J. Palte et al. ADVANCES IN THERAPY
- Dimethyl Fumarate: A Review in Relapsing-Remitting MS
- (2019) Hannah A. Blair DRUGS
- Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
- (2019) Robert T Naismith et al. Multiple Sclerosis Journal
- Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines
- (2019) B. Yamout et al. Multiple Sclerosis and Related Disorders
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis
- (2018) Alexander Rae-Grant et al. NEUROLOGY
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- Multiple sclerosis
- (2018) Massimo Filippi et al. Nature Reviews Disease Primers
- Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis
- (2017) Tessa Eagle et al. Multiple Sclerosis and Related Disorders
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
- (2016) Ralf Gold et al. Multiple Sclerosis Journal
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
- (2016) Ralf Gold et al. Multiple Sclerosis Journal
- Dimethyl Fumarate: A Review in Relapsing-Remitting MS
- (2015) Emma D. Deeks DRUGS
- Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
- (2015) D. H. Miller et al. NEUROLOGY
- Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel
- (2014) J. Theodore Phillips et al. Multiple Sclerosis and Related Disorders
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
- (2011) Ralf A. Linker et al. BRAIN
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now